Copy to clipboard 
Smith+Nephew reported 3Q19 orthopedic revenue of USD $852 million, +4.7% vs. 3Q18.
- Updated 2019 full year guidance to the range of $5,095.3 million (+3.9%) to $5,144.3 million (+4.9%)
- Knees and hips rebounded after a soft 2Q19, assisted by double-digit year over year growth from NAVIO and assets acquired from Brainlab in May 2019
- Company sees long-term opportunities in use of tech and big data, including mobile apps, wearable devices and artificial intelligence
- New OR30 dual mobility hip with OXINIUM bearing surface was submitted to FDA earlier this year; once cleared, will be one of the company’s largest product launches ever. Trauma grew moderately, driven by the global rollout of the EVOS system that expanded to wrist plates in 3Q and will include large plates in the future; INTERTAN nails grew in the double-digits and were a meaningful contributor to trauma segment growth
- Sports medicine grew slightly above market average (Note: we include REGENTEN in our Orthobiologics segment instead of sports medicine); sports medicine enabling technology products grew 0.8% vs. 3Q18, reversing a string of negative quarters for products that have been under pressure since 2016
- The outsized growth for orthobiologics is due to revenue included from Smith+Nephew’s April 2019 acquisition of Osiris Therapeutics; per leadership, REGENTEN was an important driver for the company’s U.S. sales growth
- The company is nearing its first development milestone after the acquisition of Atracsys, whose fusionTrack 500 optical tracking camera will be a core enabling technology for SNN’s robotics-assisted surgical platform expected to be available in early to mid-2020; further, with the acquisition of Brainlab’s joint replacement business, SNN has an installed base of 500 surgical navigation units and expects to introduce a new hip application in 2020
- ORTHOWORLD projects Smith+Nephew full year 2019 orthopedic revenue of $3,638 million, +5% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows (USD $ millions).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $417.3 | $400.1 | $17.2 | 4.3% |
| Knees | $259.0 | $245.0 | $14.0 | 5.7% |
| Hips | $145.0 | $142.0 | $3.0 | 2.1% |
| Extremities | $13.3 | $13.1 | $0.2 | 1.7% |
| Trauma | $106.7 | $104.9 | $1.8 | 1.7% |
| Sports Medicine | $310.9 | $300.5 | $10.5 | 3.5% |
| Orthobiologics | $17.1 | $8.6 | $8.6 | 100% |
| Total | $852.0 | $814.0 | $38.0 | 4.7% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,304.6 | $1,283.2 | $21.4 | 1.7% |
| Knees | $812.0 | $791.0 | $21.0 | 2.7% |
| Hips | $453.0 | $453.0 | $0.0 | 0% |
| Extremities | $39.6 | $39.2 | $0.4 | 1.1% |
| Trauma | $317.4 | $313.8 | $3.6 | 1.1% |
| Sports Medicine | $957.0 | $939.9 | $17.2 | 1.8% |
| Orthobiologics | $44.0 | $26.2 | $17.8 | 68.1% |
| Total | $2,623.0 | $2,563.0 | $60.0 | 2.3% |
ORTHOWORLD estimates sales by geographic region as follows (USD $ millions).
| Geographic Region | 3Q19 | 3Q18 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $426.7 | $396.2 | $30.5 | 7.7% |
| Ex-US | $425.3 | $417.8 | $7.5 | 1.8% |
| Total | $852.0 | $814.0 | $38.0 | 4.7% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Smith+Nephew reported 3Q19 orthopedic revenue of USD $852 million, +4.7% vs. 3Q18.
Updated 2019 full year guidance to the range of $5,095.3 million (+3.9%) to $5,144.3 million (+4.9%)
Knees and hips rebounded after a soft 2Q19, assisted by double-digit year over year growth from NAVIO and assets acquired from Brainlab in May...
Smith+Nephew reported 3Q19 orthopedic revenue of USD $852 million, +4.7% vs. 3Q18.
- Updated 2019 full year guidance to the range of $5,095.3 million (+3.9%) to $5,144.3 million (+4.9%)
- Knees and hips rebounded after a soft 2Q19, assisted by double-digit year over year growth from NAVIO and assets acquired from Brainlab in May 2019
- Company sees long-term opportunities in use of tech and big data, including mobile apps, wearable devices and artificial intelligence
- New OR30 dual mobility hip with OXINIUM bearing surface was submitted to FDA earlier this year; once cleared, will be one of the company’s largest product launches ever. Trauma grew moderately, driven by the global rollout of the EVOS system that expanded to wrist plates in 3Q and will include large plates in the future; INTERTAN nails grew in the double-digits and were a meaningful contributor to trauma segment growth
- Sports medicine grew slightly above market average (Note: we include REGENTEN in our Orthobiologics segment instead of sports medicine); sports medicine enabling technology products grew 0.8% vs. 3Q18, reversing a string of negative quarters for products that have been under pressure since 2016
- The outsized growth for orthobiologics is due to revenue included from Smith+Nephew’s April 2019 acquisition of Osiris Therapeutics; per leadership, REGENTEN was an important driver for the company’s U.S. sales growth
- The company is nearing its first development milestone after the acquisition of Atracsys, whose fusionTrack 500 optical tracking camera will be a core enabling technology for SNN’s robotics-assisted surgical platform expected to be available in early to mid-2020; further, with the acquisition of Brainlab’s joint replacement business, SNN has an installed base of 500 surgical navigation units and expects to introduce a new hip application in 2020
- ORTHOWORLD projects Smith+Nephew full year 2019 orthopedic revenue of $3,638 million, +5% vs. 2018
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows (USD $ millions).
| 3Q19 | 3Q18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $417.3 | $400.1 | $17.2 | 4.3% |
| Knees | $259.0 | $245.0 | $14.0 | 5.7% |
| Hips | $145.0 | $142.0 | $3.0 | 2.1% |
| Extremities | $13.3 | $13.1 | $0.2 | 1.7% |
| Trauma | $106.7 | $104.9 | $1.8 | 1.7% |
| Sports Medicine | $310.9 | $300.5 | $10.5 | 3.5% |
| Orthobiologics | $17.1 | $8.6 | $8.6 | 100% |
| Total | $852.0 | $814.0 | $38.0 | 4.7% |
| 9Mo 19 | 9Mo 18 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $1,304.6 | $1,283.2 | $21.4 | 1.7% |
| Knees | $812.0 | $791.0 | $21.0 | 2.7% |
| Hips | $453.0 | $453.0 | $0.0 | 0% |
| Extremities | $39.6 | $39.2 | $0.4 | 1.1% |
| Trauma | $317.4 | $313.8 | $3.6 | 1.1% |
| Sports Medicine | $957.0 | $939.9 | $17.2 | 1.8% |
| Orthobiologics | $44.0 | $26.2 | $17.8 | 68.1% |
| Total | $2,623.0 | $2,563.0 | $60.0 | 2.3% |
ORTHOWORLD estimates sales by geographic region as follows (USD $ millions).
| Geographic Region | 3Q19 | 3Q18 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $426.7 | $396.2 | $30.5 | 7.7% |
| Ex-US | $425.3 | $417.8 | $7.5 | 1.8% |
| Total | $852.0 | $814.0 | $38.0 | 4.7% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
